Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 6/20 | 0.62 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.61 |
| ▸ | PLG | P00747 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 7/20 | 0.57 |
| ▸ | CTSL | P07711 | 6/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9136357 | 0.91 | CTSK (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL10953796 | 0.90 | CYP1A2 (0.61) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL9819553 | 0.89 | CYP1A2 (0.60) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL9574094 | 0.89 | CYP1A2 (0.60) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL10953712 | 0.89 | CTSK (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL7510804 | 0.89 | CYP1A2 (0.60) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL10957418 | 0.87 | CYP1A2 (0.58) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL15318479 | 0.87 | CA5A (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL11436292 | 0.87 | CYP1A2 (0.58) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL11517210 | 0.87 | CYP1A2 (0.58) | CYP1A2CTSKTPSAB1PLGPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207107-B2 | Di-amido gellant for use in consumer product compositions | THE PROCTER & GAMBLE COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8168579-B2 | Fluid detergent compositions comprising a di-amido gellant, and processes for making | THE PROCTER AND GAMBLE COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| US-20110220536-A1 | Fluid Detergent Compositions Comprising a Di-Amido Gellant, and Processes for Making | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | DAGLA, GNPAT, CDIPT | CYP1A2 835/4885CTSK 2957/4885TPSAB1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.